PL3402811T3 - Analogi egf(a) z podstawnikami kwasu tłuszczowego - Google Patents

Analogi egf(a) z podstawnikami kwasu tłuszczowego

Info

Publication number
PL3402811T3
PL3402811T3 PL17701078T PL17701078T PL3402811T3 PL 3402811 T3 PL3402811 T3 PL 3402811T3 PL 17701078 T PL17701078 T PL 17701078T PL 17701078 T PL17701078 T PL 17701078T PL 3402811 T3 PL3402811 T3 PL 3402811T3
Authority
PL
Poland
Prior art keywords
egf
analogues
fatty acid
acid substituents
substituents
Prior art date
Application number
PL17701078T
Other languages
English (en)
Inventor
Jianhe Chen
Jesper F. Lau
János Tibor Kodra
Birgit Wieczorek
Lars Linderoth
Henning THØGERSEN
Salka Elbøl RASMUSSEN
Patrick William Garibay
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of PL3402811T3 publication Critical patent/PL3402811T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF] (urogastrone)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
PL17701078T 2016-01-13 2017-01-13 Analogi egf(a) z podstawnikami kwasu tłuszczowego PL3402811T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2016070791 2016-01-13
CN2016076580 2016-03-17
EP16195965 2016-10-27
EP17701078.2A EP3402811B1 (en) 2016-01-13 2017-01-13 Egf(a) analogues with fatty acid substituents
PCT/EP2017/050668 WO2017121850A1 (en) 2016-01-13 2017-01-13 Egf(a) analogues with fatty acid substituents

Publications (1)

Publication Number Publication Date
PL3402811T3 true PL3402811T3 (pl) 2022-07-11

Family

ID=57868232

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17701078T PL3402811T3 (pl) 2016-01-13 2017-01-13 Analogi egf(a) z podstawnikami kwasu tłuszczowego

Country Status (26)

Country Link
US (2) US10822385B2 (pl)
EP (1) EP3402811B1 (pl)
JP (2) JP6797926B2 (pl)
KR (1) KR102417487B1 (pl)
CN (1) CN108473550B (pl)
AU (1) AU2017207862B2 (pl)
BR (1) BR112018013820A2 (pl)
CA (1) CA3010756A1 (pl)
CL (1) CL2018001868A1 (pl)
CO (1) CO2018007440A2 (pl)
DK (1) DK3402811T3 (pl)
ES (1) ES2916998T3 (pl)
HR (1) HRP20220720T1 (pl)
HU (1) HUE058647T2 (pl)
IL (1) IL260043A (pl)
LT (1) LT3402811T (pl)
MX (1) MX2018008681A (pl)
MY (1) MY195199A (pl)
PE (1) PE20181376A1 (pl)
PH (1) PH12018501502A1 (pl)
PL (1) PL3402811T3 (pl)
RS (1) RS63298B1 (pl)
RU (1) RU2747877C2 (pl)
SA (1) SA518391996B1 (pl)
SI (1) SI3402811T1 (pl)
WO (1) WO2017121850A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108699006B (zh) 2016-01-13 2021-11-05 格吕伦塔尔有限公司 3-((杂-)芳基)-8-氨基-2-氧代-1，3-氮杂-螺-[4.5]-癸烷衍生物
AU2017206911B2 (en) 2016-01-13 2020-07-09 Grünenthal GmbH 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
LT3402811T (lt) 2016-01-13 2022-06-10 Novo Nordisk A/S Egf(a) analogai su riebalų rūgščių pakaitais
AU2017206910B2 (en) 2016-01-13 2020-07-16 Grünenthal GmbH 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US20170197947A1 (en) 2016-01-13 2017-07-13 Gruenenthal Gmbh 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives
TW201918494A (zh) 2017-07-19 2019-05-16 丹麥商諾佛 儂迪克股份有限公司 雙功能性化合物
MA49617A (fr) * 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées
WO2019023295A1 (en) * 2017-07-27 2019-01-31 Saint Louis University HUMAN EPIDERMAL GROWTH FACTOR MODIFIED BY FATTY ACID
MA53809A (fr) 2018-10-05 2022-01-12 Novo Nordisk As Composés bifonctionnels comprenant des peptides d'insuline et des peptides d'egf(a)
MX2021010767A (es) 2019-03-22 2021-09-28 3M Innovative Properties Company Sistema de proteccion contra caidas con sistema de monitoreo.
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
AU2020326265A1 (en) 2019-08-07 2022-02-03 Novo Nordisk A/S Solid compositions comprising an EGF(A) derivative and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
IL291893A (en) 2019-11-07 2022-06-01 Novo Nordisk As Solid preparations comprising a pcsk9 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino) caprylic acid
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080050576A (ko) 2005-07-29 2008-06-09 앰프로틴 코포레이션 키메릭 치료제
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
WO2009022006A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
JP5806110B2 (ja) * 2008-04-23 2015-11-10 アムジエン・インコーポレーテツド 中和プロタンパク質コンベルターゼズブチリシンケクシン９型（ｐｃｓｋ９）変形物及びその使用
US8673850B2 (en) 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
TWI445716B (zh) * 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
US8939592B2 (en) 2010-08-02 2015-01-27 Nec Corporation Polarizer and light-emitting device
CN102153652A (zh) 2010-12-10 2011-08-17 浙江大学 一种融合蛋白的表达方法及用途
WO2012110422A1 (en) 2011-02-15 2012-08-23 Novo Nordisk A/S Long-acting il-1 receptor antagonists
MX2013015311A (es) * 2011-06-20 2014-03-31 Genentech Inc Polipeptidos de enlace de pcsk9 y metodos de uso.
JP6352806B2 (ja) * 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
WO2013093009A1 (en) * 2011-12-21 2013-06-27 Novo Nordisk A/S N -terminally modified insulin derivatives
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
AR092076A1 (es) 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
MX2015002985A (es) 2012-09-07 2015-06-22 Sanofi Sa Proteinas de fusion para el tratamiento de un sindrome metabolico.
RU2683039C2 (ru) * 2013-04-18 2019-03-26 Ново Нордиск А/С Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
BR112016017402A2 (pt) 2014-02-21 2017-10-17 Medimmune Ltd fusões anti-pcsk9~glp-1 e métodos para uso
CN106536547A (zh) * 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
CA2979617C (en) * 2015-03-19 2024-01-02 Institut De Cardiologie De Montreal Grp94 derived polypeptides for inhibiting pcsk9 and methods of use
CN105367884A (zh) 2015-11-02 2016-03-02 陈薇 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法
LT3402811T (lt) 2016-01-13 2022-06-10 Novo Nordisk A/S Egf(a) analogai su riebalų rūgščių pakaitais
TW201918494A (zh) 2017-07-19 2019-05-16 丹麥商諾佛 儂迪克股份有限公司 雙功能性化合物
MA49617A (fr) 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées

Also Published As

Publication number Publication date
JP2019505521A (ja) 2019-02-28
US20190016768A1 (en) 2019-01-17
IL260043A (en) 2018-07-31
MX2018008681A (es) 2018-09-17
PH12018501502A1 (en) 2019-03-25
RS63298B1 (sr) 2022-07-29
HRP20220720T1 (hr) 2022-09-30
CO2018007440A2 (es) 2018-09-28
KR102417487B1 (ko) 2022-07-06
CN108473550B (zh) 2022-11-22
JP6797926B2 (ja) 2020-12-09
CL2018001868A1 (es) 2018-08-31
LT3402811T (lt) 2022-06-10
EP3402811A1 (en) 2018-11-21
CA3010756A1 (en) 2017-07-20
CN108473550A (zh) 2018-08-31
BR112018013820A2 (pt) 2018-12-11
DK3402811T3 (da) 2022-06-13
MY195199A (en) 2023-01-11
RU2747877C2 (ru) 2021-05-17
ES2916998T3 (es) 2022-07-06
AU2017207862A1 (en) 2018-07-05
AU2017207862B2 (en) 2020-12-17
US20200407409A1 (en) 2020-12-31
PE20181376A1 (es) 2018-09-05
US10822385B2 (en) 2020-11-03
EP3402811B1 (en) 2022-03-30
RU2018127882A (ru) 2020-02-13
KR20180100177A (ko) 2018-09-07
WO2017121850A1 (en) 2017-07-20
RU2018127882A3 (pl) 2020-06-19
SI3402811T1 (sl) 2022-06-30
SA518391996B1 (ar) 2021-07-14
JP2021035989A (ja) 2021-03-04
HUE058647T2 (hu) 2022-09-28

Similar Documents

Publication Publication Date Title
IL260043A (en) egf(a) analogues with fatty acid converters
ZA201805705B (en) Pth prodrugs
IL248632B (en) micellar nanocomplex
IL265588A (en) Treprostinil prodrugs
EP2902708A4 (en) GAS TURBINE BURNING CHAMBER FOR SEVERAL FUELS
GB2595424B (en) A connector arrangement
GB201517808D0 (en) A shroud assembly
GB201611674D0 (en) A turbine arrangement
GB2549510B (en) A Connector
GB201518766D0 (en) A head up display
LT3070231T (lt) Nuimama danga su užspaudžiama jungtimi
GB201419661D0 (en) Duct assembly with a connector
ZA201607059B (en) Omega-3 analogues
GB201513069D0 (en) A connector
PL3280879T3 (pl) Układ do turbiny
GB201518909D0 (en) A formulation
HK1217152A2 (zh) 種新型導風口結構
PT3402811T (pt) Análogos de egf(a) com substituintes de ácidos gordos
EP3102980A4 (en) High-power ultra-short pulse fiber laser-illuminated projector
AU201615213S (en) A head board
LT3100836T (lt) Plokštės gamyba
GB201513331D0 (en) A Banner Assembly
GB201507081D0 (en) Nozzle tip manufacturing
EP3658527A4 (en) ACRYLIC ACID ANALOGUES
GB201521110D0 (en) Beyond MK4 A